Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/")
 
(19 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
{| class="wikitable" style="text-align:center; width:50%;"
+
<span id="BackToTop"></span>
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
|-
+
[[#top|Back to Top]]
−
|style="background-color:#F0F0F0"|[[File:Elizabethdavis2.jpg|frameless|upright=0.3|center]]
+
</div>
−
|<big>[[User:Elizabethdavis|Elizabeth J. Davis, MD]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/ejdavis25 ejdavis25]
+
{{#lst:Editorial board transclusions|sarcoma}}
−
|-
 
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 
*[[Ewing sarcoma]]
 
*[[Ewing sarcoma]]
 +
*[[Giant-cell tumor of bone]]
 
*[[Osteosarcoma]]
 
*[[Osteosarcoma]]
 
</big>
 
</big>
 
=Guidelines=
 
=Guidelines=
−
==[http://www.esmo.org/ ESMO]==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
+
==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan==
−
==[https://www.nccn.org/ NCCN]==
+
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed]
−
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]
+
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed]
 +
**'''2014:''' [https://doi.org/10.1093/annonc/mdu256 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/25210081/ PubMed]
 +
**'''2012:''' [https://doi.org/10.1093/annonc/mds254 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997441/ PubMed]
 +
**'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed]
 +
 
 +
==NCCN==
 +
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer]
 +
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed]
 +
*'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed]
 +
*'''2007:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2007.0037 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/17442233/ PubMed]
 +
*'''2005:''' Biermann et al. Bone cancer clinical practice guidelines. [https://pubmed.ncbi.nlm.nih.gov/19817025/ PubMed]
  
 
=Chondrosarcoma, all lines of therapy=
 
=Chondrosarcoma, all lines of therapy=
Line 27: Line 36:
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
  
−
=Giant-cell tumor of bone, all lines of therapy=
+
=Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy=
−
==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}==
+
*Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
−
===Regimen {{#subobject:f50a28|Variant=1}}===
 
−
{| class="wikitable" style="width: 50%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010 (Amgen 20040215)]
 
−
|style="background-color:#91cf61"|Phase II (RT)
 
−
|-
 
−
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext Chawla et al. 2013 (Amgen 20062004)]
 
−
|style="background-color:#91cf61"|Phase II (RT)
 
−
|-
 
−
|}
 
−
====Chemotherapy====
 
−
*[[Denosumab (Xgeva)]] as follows:
 
−
**Cycle 1: 120 mg SC once per day on days 1, 8, 15
 
−
**Cycle 2 onwards: 120 mg SC once on day 1
 
−
 
 
−
====Supportive medications====
 
−
*Calcium 500 mg PO once per day
 
−
*Vitamin D 400 IU PO once per day
 
−
 
 
−
'''28-day cycles'''
 
−
 
 
−
===References===
 
−
# '''Amgen 20040215:''' Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed]
 
−
# '''Amgen 20062004:''' Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23867211 PubMed]
 
−
## '''Update:''' Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30663-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31704134 PubMed]
 
−
 
 
−
=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy=
 
−
*Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
  
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Bone sarcomas]]
 
[[Category:Bone sarcomas]]

Latest revision as of 17:51, 23 June 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
0 regimens on this page
0 variants on this page


Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO/EURACAN/GENTURIS/PaedCan

NCCN

Chondrosarcoma, all lines of therapy

Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy

Retrieved from "https://hemonc.org/w/index.php?title=Bone_sarcoma&oldid=86505"